切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (06) : 631 -634. doi: 10.3877/cma.j.issn.1674-3946.2020.06.027

所属专题: 文献

论著

BRAFV600E突变在cN0期PTMC颈中央区淋巴结转移中的预测价值
宋创业1, 严丽2,(), 孟艳林3, 刘冰1, 尚培中1, 南润玲1, 吕瑞昌1, 张江华1, 张克俭1   
  1. 1. 075000 河北张家口,中国人民解放军陆军第八十一集团军医院普通外科
    2. 050005 石家庄,河北医科大学第二医院腺体外科
    3. 075000 河北张家口,中国人民解放军陆军第八十一集团军医院疾病预防控制科
  • 收稿日期:2020-04-20 出版日期:2020-12-26
  • 通信作者: 严丽

The predictive value of BRAFV600E mutation for central lymph node metastasis (CLNM) in patients with cN0 papillary thyroid microcarcinoma (PTMC)

Chuangye Song1, Li Yan2,(), Yanlin Meng3, Bing Liu1, Peizhong Shang1, Runling Nan1, Ruichang Lyv1, Jianghua Zhang1, Kejian Zhang1   

  1. 1. Department of General Surgery, the 81st Liberation Army Hospital, Hebei 075000, China
    2. Department of Glandular Surgery, the Second Hospital of Hebei Medical University, Hebei 050005, China
    3. Department of Infection control division, the 81st Liberation Army Hospital, Hebei 075000, China
  • Received:2020-04-20 Published:2020-12-26
  • Corresponding author: Li Yan
  • About author:
    Corresponding author: Yan Li, Email:
引用本文:

宋创业, 严丽, 孟艳林, 刘冰, 尚培中, 南润玲, 吕瑞昌, 张江华, 张克俭. BRAFV600E突变在cN0期PTMC颈中央区淋巴结转移中的预测价值[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(06): 631-634.

Chuangye Song, Li Yan, Yanlin Meng, Bing Liu, Peizhong Shang, Runling Nan, Ruichang Lyv, Jianghua Zhang, Kejian Zhang. The predictive value of BRAFV600E mutation for central lymph node metastasis (CLNM) in patients with cN0 papillary thyroid microcarcinoma (PTMC)[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(06): 631-634.

目的

探讨BRAFV600E突变在cN0期甲状腺微小乳头状癌(PTMC)颈中央区淋巴结转移(CLNM)的临床意义及预测价值。

方法

回顾性分析2017年1月至2020年1月经手术治疗、病理证实的222例cN0期PTMC患者的临床资料,分析BRAFV600E突变阳性与PTMC患者CLNM的相关性。应用SPSS 23.0统计软件分析数据,单因素分析采用χ2检验分析,多因素分析采用Logistic回归分析;P<0.05为差异有统计学意义。

结果

222例PTMC患者94例(42.3%)存在CLNM;肿瘤大小、肿瘤多灶性、包膜侵犯、BRAFV600E突变是CLNM的独立危险因素(P<0.05),发生CLNM的风险更高;BRAFV600E突变(OR=2.445,95%CI:1.557~3.840)是影响CLNM最重要的独立危险因素。

结论

PTMC具有较高的CLNM,BRAFV600E突变阳性时应常规行预防性中央区淋巴结清扫术;BRAFV600E突变可有效预测cN0期PTMC患者是否存在CLNM。

Objective

To investigate the clinical significance and predictive value of BRAFV600E mutation for central lymph node metastasis (CLNM) in patients with cN0 papillary thyroid microcarcinoma (PTMC).

Methods

A retrospective analysis was performed in 222 patients with pathologically confirmed cN0 PTMC from January 2017 to January 2020. The correlation between BRAFV600E mutation and CLNM of PTMC was analyzed. Statistical analysis was performed by using SPSS 23.0 software. The χ2 test was used for univariate analysis and Logistic regression was used for multivariate analysis. A P value of < 0.05 were considered as statistically significant difference.

Results

Among 222 patients, there were 94 cases (42.3%) of CLNM. Tumor size, multifocality, capsular invasion and BRAFV600E mutation were independent risk factors for CLNM (P<0.05), however BRAFV600E mutation (OR=2.445, 95% CI: 1.557~3.840) was the most important independent risk factor for CLNM.

Conclusion

PTMC patients had a high rate of CLNM, and prophylactic central lymph node clearance should be routinely performed in patients with BRAFV600E mutation. BRAFV600E mutation could effectively predict CLNM in patients with cN0 PTMC.

表1 222例PTMC患者的临床病理资料
图2 甲状腺微小乳头状癌组织中BRAFV600E突变蛋白低表达(3-4分,400x)
图4 甲状腺微小乳头状癌组织中BRAFV600E突变蛋白高表达(9-12分,400x)
表2 222例PTMC患者免疫组织化学评分与颈中央区淋巴结转移相关性分析
表3 222例PTMC患者BRAFV600E突变与颈中央区淋巴结转移的相关性分析[例(%)]
表4 222例PTMC患者临床病理特征与颈中央区淋巴结转移相关性多因素分析
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2]
贺靖,周明霞.甲状腺癌肿瘤干细胞及其分子调控机制的研究进展[J].外科理论与实践,2017, 22( 2): 178-182.
[3]
布都沙塔尔·吐尔地,阿斯耶姆·图尔荪,米也赛尔·肉孜.甲状腺微小乳头状癌患者颈部淋巴结转移的相关危险因素分析[J].临床合理用药杂志,2020, 13(8): 153-155.
[4]
Randle RW, Bushman NM, Orne J, et al. Papillary Thyroid Cancer: The Good and Bad of the " Good Cancer" [J]. Thyroid,2017, 27(7): 902-907.
[5]
陈亮,彭泉,于华杰,等.甲状腺微小乳头状癌中央区淋巴结转移的危险因素分析[J].中国现代普通外科进展,2019, 22(10): 818-820.
[6]
Zheng XQ, Peng C, Gao M, et al.Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients[J]. Cancer Biol Med,2019, 16(1): 121-130.
[7]
王晓涛,杨春伟,卢伟胜,等.甲状腺微小乳头状癌中央区淋巴结转移相关的临床因素研究[J].中国煤炭工业医学杂志,2016, 19(9): 1301-1303.
[8]
靳凯,成绥生,谷瀚博.甲状腺微小乳头状癌中央区淋巴结转移的危险因素分析[J].医学综述,2019, 25(4): 828-832.
[9]
Gambardella C, Tartaglia E, Nunziata A, et al. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients[J]. World J Surg Oncol, 2016, 14(1): 247.
[10]
林岩松,杨雪.甲状腺微小癌~(131)I治疗[J].中国实用外科杂志,2016, 36(5): 527-530.
[11]
Moo TA, Mcgill J, Allendorf J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma[J]. World J Surg, 2010, 34(6): 1187-1191.
[12]
Lim RZM, Ooi JY, Tan JH, et al. Outcome of Cervical Lymph Nodes Dissection for Thyroid Cancer with Nodal Metastases: A Southeast Asian 3-Year Experience[J]. Int J Surg Oncol, 2019, 2019: 6109643.
[13]
Calo PG, Pisano G, Medas F, et al. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment?[J]. World J Surg Oncol, 2014, 12: 152.
[14]
董凌翔,贺亮,张浩.甲状腺癌中央区淋巴结清扫术后并发乳糜漏14例临床分析[J].中国实用外科杂志,2019, 39(2): 173-177.
[15]
王宇,沈强,渠宁.分化型甲状腺癌颈侧区淋巴结清扫术中神经损伤的预防[J].中国实用外科杂志,2018, 38(6): 624-628.
[16]
Dobrinja C, Troian M, Mis Cipolat T,et al.Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center[J]. Int J Surg,2017, 41 Suppl 1: S40-S47.
[17]
张浩,孙威.甲状腺乳头状癌行预防性中央区淋巴结清扫的争议、共识与对策[J].中国实用外科杂志,2018, 38(2): 187-191.
[18]
张颖,罗渝昆,张艳,等.超声引导下细针穿刺细胞学检查联合BRAF~(V600E)检测与甲状腺乳头状癌侵袭性病理特征的相关性[J].中国医学科学院学报,2019, 41(4): 517-523.
[19]
冯勤,李忠武,刘卉,等.免疫组织化学检测63例原发甲状腺癌中BRAF~(V600E)突变及其价值研究[J].中国实用内科杂志,2018, 38(12): 1188-1190.
[20]
Abd Elmageed ZY, Sholl AB, Tsumagari K,et al. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer[J]. Surgery, 2017, 161(4): 1122-1128.
[21]
Qu HJ, Qu XY, Hu Z, et al. The synergic effect of BRAF(V600E) mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma[J]. Endocr J, 2018, 65(1): 113-120.
[22]
Zhang Q, Wang ZM, Meng XY, et al. Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases[J].Asian J Surg,2019, 42(4): 571-576.
[1] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[2] 麻紫月, 王贞文, 张强, 赵代伟, 张翊伦. 右侧喉不返神经1例报告[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 115-116.
[3] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[4] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[5] 田文. 甲状腺癌功能性根治颈淋巴结清扫术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 482-482.
[6] 王宇, 徐芳泉, 周旋, 姚晓峰, 李强. 不断提高分化型甲状腺癌根治性切除规范化[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 473-476.
[7] 孙辉, 李长霖. 分化型甲状腺癌根治性切除术中的关键考量与策略[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 477-481.
[8] 高一飞, 刘根祥, 孙长华, 周广军. 喉返神经监测在无充气腋窝入路腔镜单侧甲状腺切除+中央区淋巴结清扫术中的应用效果[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 483-486.
[9] 李云龙, 夏旭良, 江志强, 刘伟, 刘凯, 唐立, 刘昊中, 张思远. 三种方法治疗分化型甲状腺癌的临床疗效[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 487-489.
[10] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[11] 达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[12] 何羽. 腔镜微创手术治疗分化型甲状腺癌的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 456-458.
[13] 宋红霞, 吴玩呈. 内镜下甲状腺手术切口入路发展的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 470-472.
[14] 游涛建, 任林, 马宇. cT1-2N0期PTMC经口腔前庭入路腔镜甲状腺切除术后引流与否的可行性研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 311-314.
[15] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
阅读次数
全文


摘要